Serious cycling can result in serious erectile dysfunction
October 1st 2005Hamburg, Germany--Serious male cycling enthusiasts might want to consider taking a phosphodiesterase type-5 inhibitor prior to a long ride to prevent pressure-induced hypo-oxygenation of the penis, according to German researchers.
Alpha-blockers may improve erectile dysfunction in men with LUTS
October 1st 2005Denver--Studies in recent years have shown a strong correlation between lower urinary tract symptom severity and erectile dysfunction, but there have also been contradictory reports on the effect of BPH medications on sexual health.
Buying used medical equipment: Does it make sense?
October 1st 2005Two significant trends are having an impact on most urology practices today. First, most practices, including my own, are experiencing a decrease in reimbursement and rising overhead expenses. This ultimately translates to a decrease in net income.
AUA addresses issues in education, certification
October 1st 2005AUA recently made a number of key appointments to its staff and board of directors, and the association is examining how it will adapt to changes in physician education, board certification, and training. In this exclusive interview, Joseph N. Corriere, Jr, MD, whose 1-year term as AUA president began in May, discusses these initiatives as well as a number of socioeconomic issues currently affecting practicing urologists. Dr. Corriere is professor of urology at the University of Texas M.D. Anderson Cancer Center, Houston. The interview was conducted by UT Editorial Consultant Richard D. Williams, MD, professor and chairman of the department of urology at the University of Iowa, Iowa City.
Three factors predict death from recurring prostate cancer
October 1st 2005Baltimore--Researchers at the Brady Urological Institute at Johns Hopkins have identified three risk factors that help determine whether a patient's risk of death from recurrent prostate cancer is high or low following surgery. This insight will help urologists to better determine whether aggressive or conservative treatment is best for many patients, according to the authors of the study, published in JAMA (2005; 294:433-9).
Chemo's impact on QoL often outweighs benefit in advanced PCa
September 19th 2005Half of men who suffer from late-stage prostate cancer would consider chemotherapy a treatment option, and 65% believe the impact on quality of life outweighs its benefit, according to a new survey released by Us TOO International Prostate Cancer Education & Support Network.
High-dose radiation therapy better at reducing PCa recurrence
September 19th 2005Men with localized prostate cancer who receive high-dose external radiation therapy are less likely to have cancer recurrence than those who receive conventional-dose radiation therapy, according to a randomized study published in JAMA (2005; 294:1233-9).
Urologists, other specialists see decline in compensation
September 19th 2005Although overall physician compensation flattened out in 2004, compensation growth for specialty physicians fell behind that of primary care physicians for the first time in several years, according to a report from the Medical Group Management Association.
Senator continues push for better disclosure of blindness risk with ED drugs
September 7th 2005Sen. Chuck Grassley (R-IA) has sent a second strongly worded letter to the FDA pushing for better disclosure of the blindness risk associated with phosphodiesterase type-5 inhibitors for erectile dysfunction.
Two-pronged approach relieves refractory CPPS pain
September 7th 2005Combining physical and psychological therapy for chronic pelvic pain syndrome (CPPS, or chronic nonbacterial prostatitis) can provide relief for many patients who have pain refractory to conventional treatments, according Stanford (CA) University researchers.
TUMT is found safe, effective alternative to surgery
September 7th 2005Minimally invasive transurethral microwave thermotherapy using the ProstaLund Feedback Treatment system (PLFT; ProstaLund, Los Angeles) is a safe and effective alternative to surgery in patients with symptomatic BPH and persistent urinary retention, according to Scandinavian investigators.
Docetaxel clears another hurdle in high-risk prostate Ca trials
September 7th 2005Initial findings from a continuing phase II multicenter study of docetaxel (Taxotere) as adjuvant therapy in radical prostatectomy patients at high risk of recurrence have shown that the drug is well tolerated, with reversible side effects.
Prostate cancer cell growth halted with calcitriol-NSAID combination
September 7th 2005The growth of prostate cancer cells can be halted by combining a form of vitamin D with low doses of a nonsteroidal anti-inflammatory drug, according to results of an in vitro study by researchers at the Stanford (CA) University School of Medicine.
Specific gene expression patterns identified in women with stress incontinence
September 2nd 2005General patterns of genetic expression have been identified in postmenopausal women with stress urinary incontinence that are not present in postmenopausal women without the condition. This is the first step toward being able to identify patients most at risk for stress incontinence early on, with the eventual hope of helping to prevent the condition, said researchers from the University of Rochester (NY) Medical Center.
Biological mesh may offer advantage in patients with cystocele
September 2nd 2005Biological mesh is likely an effective material to use for the correction of medium- and high-grade anterior compartment vaginal defects and will likely be more readily adapted by the body, according to research presented here on Friday.
Solifenacin shows advantage in several OAB outcome measures
September 2nd 2005Two newer-generation antimuscarinic agents — solifenacin succinate (Vesicare) and tolterodine tartrate extended-release (Detrol LA) — improve symptoms of overactive bladder, but solifenacin appears to provide superior outcomes, partly because it offers a flexible dosing regimen, researchers say.